ONCO Stock Overview
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Onconetix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.12 |
| 52 Week High | US$1.58 |
| 52 Week Low | US$0.13 |
| Beta | 3.38 |
| 1 Month Change | -22.90% |
| 3 Month Change | -28.30% |
| 1 Year Change | -88.57% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.78% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation
Jan 24
Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia
Oct 11Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot
Aug 17Blue Water Vaccines in pact to study Alzheimer’s vaccine
Jul 20Blue Water Vaccines: Estimates And Expectations
May 17Shareholder Returns
| ONCO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -20.2% | -4.2% | -3.7% |
| 1Y | -88.6% | -2.0% | 20.5% |
Return vs Industry: ONCO underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: ONCO underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ONCO volatility | |
|---|---|
| ONCO Average Weekly Movement | 39.6% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ONCO's share price has been volatile over the past 3 months.
Volatility Over Time: ONCO's weekly volatility has increased from 23% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Ralph Schiess | onconetix.gcs-web.com |
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children’s to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others.
Onconetix, Inc. Fundamentals Summary
| ONCO fundamental statistics | |
|---|---|
| Market cap | US$2.79m |
| Earnings (TTM) | -US$37.41m |
| Revenue (TTM) | US$58.47k |
47.3x
P/S Ratio-0.1x
P/E RatioIs ONCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCO income statement (TTM) | |
|---|---|
| Revenue | US$58.47k |
| Cost of Revenue | US$1.19m |
| Gross Profit | -US$1.13m |
| Other Expenses | US$36.28m |
| Earnings | -US$37.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.68 |
| Gross Margin | -1,927.93% |
| Net Profit Margin | -63,986.48% |
| Debt/Equity Ratio | 693.3% |
How did ONCO perform over the long term?
See historical performance and comparison